Clinicopathological analyses of primary non-Hodgkins lymphoma of bone
ZHOU Zhi-yi, CHENG Jing, SHI Qun-li, ZHOU Xiao-jun, TIAN Xiu-chun, XIAO Qin,ZHOU Hang-bo, MA Heng-hui (Departmetn of Pathology, Nanjing General Hospital of Nanjing Military Command, Nanjing 210002,China)
Purpose To investigate the clinicopathological features, clinical prognostic indicauor of primary non-Hodgkins lymphoma of bone (PNHLB), and the value of Pax-5 in diagnosis. Methods Clinical data of PNHLB was reviewed. The relations of serum LDH, international prognostic indicator (IPI) and treatment, to the outcome were analyzed. The expression of Pax-5 were detected with EnVision staining, and the result was then compared with CD20 and CD79α. Results All 23 cases were B-lymphoma. The 5-year survival rates of 22 patients were 65.9%, unfavorable variables for survival rate were higher serum LDH, high-risk IPI (P=0.02, P=0.01). Among 23 cases, 22 were positive for Pax-5, 2 cases of T- lymphoma were negative. The staining of Pax-5, CD20 and CD79α showed no statistical significance. Conclusions In PNHLB, B-lymphoma is most, the outcome of PNHLB is good. Serum LDH and IPI may serve as indicators for prognostic assessment. Pax-5 is applicable in the diagnosis of PNHLB.
【CateGory Index】： R738